IND SWIFT LABORATORIES LIMITED Индия

Ind-Swift Laboratories Limited is a MANUFACTURER (factory).

Company Profile:

Country of Origin: India

Business Type: Manufacturer of Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates.

Overview:

Ind-Swift Laboratories Limited is a prominent Indian pharmaceutical company specializing in the research, development, and manufacturing of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. It plays a crucial role in the global pharmaceutical supply chain by providing the essential raw materials used in the production of various finished dosage forms.

Key Highlights:

- Focus on a wide range of therapeutic segments, including anti-histaminic, anti-fungal, anti-ulcer, and anti-bacterial drugs.

- Strong emphasis on research and development to innovate and optimize manufacturing processes.

- Adherence to stringent international quality standards and regulatory guidelines, such as USFDA, EDQM, and WHO-GMP.

- Significant global presence, exporting its products to numerous countries worldwide, contributing to the availability of essential medicines internationally.

Ind-Swift Laboratories Limited is dedicated to contributing to global healthcare through the production of high-quality and cost-effective pharmaceutical ingredients.

IND SWIFT LABORATORIES LIMITED India primarily manufactures and sells Active Pharmaceutical Ingredients (APIs). These APIs are supplied globally, including to markets like Uzbekistan, for use in the production of finished pharmaceutical formulations.

Key Active Pharmaceutical Ingredients (APIs) manufactured include:

Ambroxol Hydrochloride

Domperidone

Esomeprazole Magnesium Trihydrate

Fexofenadine Hydrochloride

Guaifenesin

Levocetirizine Dihydrochloride

Montelukast Sodium

Pantoprazole Sodium Sesquihydrate

Rabeprazole Sodium

Rosuvastatin Calcium

Sildenafil Citrate

Tamsulosin Hydrochloride

Telmisartan

Tramadol Hydrochloride

Valsartan

Voriconazole

While IND SWIFT LABORATORIES LIMITED focuses on API production, the larger Ind-Swift Group also manufactures finished pharmaceutical formulations across various therapeutic segments such as cardiovascular, anti-diabetic, gastroenterology, pain management, anti-infectives, respiratory, and neurology. The specific finished products sold in Uzbekistan would depend on local regulatory approvals and distribution channels.